ONC Stock Analysis: BeiGene | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 30.165m USD | 12M Return: 28.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.2M
Qual. Beats: 1
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BeOne Medicines AG (NASDAQ: ONC) is a global oncology company developing cancer treatments across the United States, China, Europe, and other international markets. Founded in 2010 and headquartered in Basel, Switzerland, the company was previously known as BeiGene, Ltd. before rebranding in May 2025. It is classified as a large-cap biotechnology company within the Health Care sector.
The companys commercial portfolio is anchored by BRUKINSA, a BTK inhibitor used to treat blood cancers, and TEVIMBRA, an anti-PD-1 checkpoint inhibitor indicated for solid tumors and blood cancers. Additional approved products include SYLVANT (for multicentric Castleman disease), BAITUOWEI (for breast cancer in premenopausal and perimenopausal women), and PARTRUVIX (for solid tumors). BTK inhibitors and PD-1 inhibitors are established drug classes in hematology and immuno-oncology, respectively, and form the core revenue base for the company.
BeOne maintains an extensive clinical-stage pipeline spanning multiple oncology modalities, including small-molecule inhibitors (such as Bcl-2, CDK4, CDK2, Pan-KRAS, and MAT2A inhibitors), antibody-drug conjugates (ADCs) targeting antigens like B7H3, B7H4, FGFR2b, and CEA, bispecific antibodies (including HER2-targeted and MUC1xCD16A candidates), and protein degraders. The pipeline diversification across targeted therapies, immuno-oncology, and next-generation biologics reflects a typical biotech strategy of balancing near-term commercial revenue with long-term pipeline optionality.
The company has established collaboration and licensing agreements with several major pharmaceutical firms, including Amgen, Bristol-Myers Squibb, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. Such partnerships are common in the biotechnology sector and are typically used to share development costs, access external innovation, and expand geographic reach for both approved products and pipeline assets.
- BRUKINSA gains market share against Calquence in BTK inhibitor space
- China revenue growth drives expansion amid reimbursement pressure
- TEVIMBRA launch accelerates with new indication approvals
| Net Income: 513.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 14.01 > 1.0 |
| NWC/Revenue: 83.46% < 20% (prev 45.81%; Δ 37.65% < -1%) |
| CFO/TA 0.15 > 3% & CFO 1.29b > Net Income 513.0m |
| Net Debt (-3.57b) to EBITDA (901.8m): -3.96 < 3 |
| Current Ratio: 3.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.8m) vs 12m ago 4.14% < -2% |
| Gross Margin: 88.31% > 18% (prev 84.81%; Δ 3.50% > 0.5%) |
| Asset Turnover: 79.74% > 50% (prev 71.49%; Δ 8.25% > 0%) |
| Interest Coverage Ratio: 12.91 > 6 (EBIT TTM 751.8m / Interest Expense TTM 58.2m) |
| A: 0.56 (Total Current Assets 6.60b - Total Current Liabilities 1.81b) / Total Assets 8.55b |
| B: -0.95 (Retained Earnings -8.09b / Total Assets 8.55b) |
| C: 0.10 (EBIT TTM 751.8m / Avg Total Assets 7.20b) |
| D: 1.26 (Book Value of Equity 4.76b / Total Liabilities 3.79b) |
| Altman-Z'' = 2.61 = A |
| DSRI: 0.93 (Receivables 948.4m/746.0m, Revenue 5.74b/4.18b) |
| GMI: 0.96 (GM 84.81% / 88.31%) |
| AQI: 0.61 (AQ_t 0.02 / AQ_t-1 0.03) |
| SGI: 1.37 (Revenue 5.74b / 4.18b) |
| TATA: -0.09 (NI 513.0m - CFO 1.29b) / TA 8.55b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of July 08, 2026, the stock is trading at USD 308.96 with a total of 311,103 shares traded. Over the past week, the price has changed by +6.54%, over one month by +14.09%, over three months by +1.69% and over the past year by +28.20%.
Current recommended Stop Loss: 296.90 (which is 3.9% or 1.3 ATR below the current price).
BeiGene has received a consensus analysts rating of 4.58. Therefore, it is recommended to buy ONC.
- StrongBuy: 15
- Buy: 8
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 412.4 | 33.5% |
P/E Trailing = 65.7783
P/E Forward = 44.0529
P/S = 5.2559
P/B = 6.3365
Revenue TTM = 5.74b USD
EBIT TTM = 751.8m USD
EBITDA TTM = 901.8m USD
Long Term Debt = 962.5m USD (from longTermDebt, last quarter)
Short Term Debt = 136.7m USD (from shortTermDebt, last quarter)
Debt = 1.22b USD (from shortLongTermDebtTotal, last quarter) + Leases 70.3m
Net Debt = -3.57b USD (calculated: Debt 1.22b - CCE 4.79b)
Enterprise Value = 26.6b USD (30.2b + Debt 1.22b - CCE 4.79b)
Interest Coverage Ratio = 12.91 (Ebit TTM 751.8m / Interest Expense TTM 58.2m)
EV/FCF = 31.41x (Enterprise Value 26.6b / FCF TTM 846.5m)
FCF Yield = 3.18% (FCF TTM 846.5m / Enterprise Value 26.6b)
FCF Margin = 14.75% (FCF TTM 846.5m / Revenue TTM 5.74b)
Net Margin = 8.94% (Net Income TTM 513.0m / Revenue TTM 5.74b)
Gross Margin = 88.31% ((Revenue TTM 5.74b - Cost of Revenue TTM 670.8m) / Revenue TTM)
Gross Margin QoQ = 88.95% (prev 90.49%)
Tobins Q-Ratio = 3.11 (Enterprise Value 26.6b / Total Assets 8.55b)
Interest Expense / Debt = 4.78% (Interest Expense 58.2m / Debt 1.22b)
Taxrate = 21.70% (142.1m / 655.2m)
NOPAT = 588.7m (EBIT 751.8m * (1 - 21.70%))
Current Ratio = 3.64 (Total Current Assets 6.60b / Total Current Liabilities 1.81b)
Debt / Equity = 0.26 (Debt 1.22b / totalStockholderEquity, last quarter 4.76b)
Debt / EBITDA = -3.96 (Net Debt -3.57b / EBITDA 901.8m)
Debt / FCF = -4.22 (Net Debt -3.57b / FCF TTM 846.5m)
Total Stockholder Equity = 4.26b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.13% (Net Income 513.0m / Total Assets 8.55b)
RoE = 12.06% (Net Income TTM 513.0m / Total Stockholder Equity 4.26b)
RoCE = 14.41% (EBIT 751.8m / Capital Employed (Equity 4.26b + L.T.Debt 962.5m))
RoIC = 8.93% (NOPAT 588.7m / Invested Capital 6.59b)
WACC = 7.60% (E(30.2b)/V(31.4b) * Re(7.76%) + D(1.22b)/V(31.4b) * Rd(4.78%) * (1-Tc(0.22)))
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 4.85%
[DCF] Terminal Value 75.44% ; FCFF base≈846.5m ; Y1≈850.0m ; Y5≈900.4m
[DCF] Fair Price = 185.2 (EV 14.0b - Net Debt -3.57b = Equity 17.6b / Shares 94.9m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.71 | # QB: 1
Revenue Correlation: 99.41 | Revenue CAGR: 50.29% | SUE: 1.65 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.53 | Chg30d=-3.69% | Revisions=+58% | Analysts=12
EPS next Quarter (2026-09-30): EPS=1.72 | Chg30d=-0.24% | Revisions=-8% | Analysts=12
EPS current Year (2026-12-31): EPS=6.51 | Chg30d=-2.62% | Revisions=+56% | GrowthEPS=+157.3% | GrowthRev=+21.1%
EPS next Year (2027-12-31): EPS=9.71 | Chg30d=+0.44% | Revisions=+31% | GrowthEPS=+49.2% | GrowthRev=+14.7%
[Analyst] Revisions Ratio: +43% (up=32, down=12)